Arax Advisory Partners’s Abivax ABVX Stock Holding History

Arax Advisory Partners’s Portfolio ABVX Stock Details ABVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-62	Closed	-$8.36K	–	3769
2025 Q4	$8.36K	Buy	+62	New	+$6.76K	﹤0.01%	2566

Other funds holding ABVX

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Helikon Investments London, United Kingdom $2.65B AUM 79.03% 1-Year Est. Return

Arax Advisory Partners's ABVX Position: Q1 2026 in Review

Arax Advisory Partners sold out of Abivax (ABVX) in Q1 2026, closing a stake of 62 shares — an estimated $8.36K sold.

Arax Advisory Partners first reported a position in ABVX in Q4 2025 and held it in 1 quarter. The position peaked at $8.36K in Q4 2025. 254 funds tracked by Wall St. Rank hold ABVX as of Q1 2026.

Arax Advisory Partners reported no remaining Abivax position as of Q1 2026 after selling out during the quarter.
Arax Advisory Partners sold 62 Abivax shares in Q1 2026, an estimated $8.36K.
Arax Advisory Partners first reported a position in Abivax in Q4 2025 and held it in 1 quarter.
Arax Advisory Partners's Abivax position peaked at $8.36K in Q4 2025.
254 funds tracked by Wall St. Rank held Abivax as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.